These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2435621)

  • 1. Pelvic exenteration: prognostic significance of regional lymph node metastasis.
    Rutledge FN; McGuffee VB
    Gynecol Oncol; 1987 Mar; 26(3):374-80. PubMed ID: 2435621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesorectal lymph node involvement and prognostic implications at total pelvic exenteration for gynecologic malignancies.
    Mourton SM; Chi DS; Sonoda Y; Alektiar KM; Venkatraman ES; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2006 Mar; 100(3):533-6. PubMed ID: 16226800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indications for primary and secondary exenterations in patients with cervical cancer.
    Marnitz S; Köhler C; Müller M; Behrens K; Hasenbein K; Schneider A
    Gynecol Oncol; 2006 Dec; 103(3):1023-30. PubMed ID: 16890276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in pelvic exenteration for gynecological malignancies.
    Baiocchi G; Guimaraes GC; Rosa Oliveira RA; Kumagai LY; Faloppa CC; Aguiar S; Begnami MD; Soares FA; Lopes A
    Eur J Surg Oncol; 2012 Oct; 38(10):948-54. PubMed ID: 22818842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pelvic exenterations for gynecological malignancies: a study of 36 cases.
    Kaur M; Joniau S; D'Hoore A; Van Calster B; Van Limbergen E; Leunen K; Penninckx F; Van Poppel H; Amant F; Vergote I
    Int J Gynecol Cancer; 2012 Jun; 22(5):889-96. PubMed ID: 22617477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pelvic exenteration, University of Michigan: 100 patients at 5 years.
    Morley GW; Hopkins MP; Lindenauer SM; Roberts JA
    Obstet Gynecol; 1989 Dec; 74(6):934-43. PubMed ID: 2586960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pelvic Exenteration in Gynecologic Cancer: La Paz University Hospital Experience.
    Moreno-Palacios E; Diestro MD; De Santiago J; Hernández A; Zapardiel I
    Int J Gynecol Cancer; 2015 Jul; 25(6):1109-14. PubMed ID: 25853383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pelvic exenterative therapy for gynecologic malignancy: an analysis of 70 cases.
    Morley GW; Lindenauer SM
    Cancer; 1976 Jul; 38(1 SUPPL):581-6. PubMed ID: 1277109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pelvic Exenteration as Potential Cure and Symptom Relief in Advanced and Recurrent Gynaecological Cancer.
    Soeda S; Furukawa S; Sato T; Ueda M; Kamo N; Endo Y; Kojima M; Nomura S; Kataoka M; Fujita S; Endo H; Takahashi T; Watanabe T; Yamada H; Fujimori K
    Anticancer Res; 2019 Oct; 39(10):5631-5637. PubMed ID: 31570460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of pelvic exenteration and reconstruction for treatment of advanced or recurrent gynecologic malignancies: Analysis of risk factors predicting recurrence and survival.
    Park JY; Choi HJ; Jeong SY; Chung J; Park JK; Park SY
    J Surg Oncol; 2007 Dec; 96(7):560-8. PubMed ID: 17708548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution.
    Jäger L; Nilsson PJ; Rådestad AF
    Int J Gynecol Cancer; 2013 May; 23(4):755-62. PubMed ID: 23407096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers.
    Fleisch MC; Pantke P; Beckmann MW; Schnuerch HG; Ackermann R; Grimm MO; Bender HG; Dall P
    J Surg Oncol; 2007 May; 95(6):476-84. PubMed ID: 17192947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort.
    Straubhar AM; Chi AJ; Zhou QC; Iasonos A; Filippova OT; Leitao MM; Awowole IO; Abu-Rustum NR; Broach VA; Jewell EL; Sandhu JS; Sonoda Y
    Gynecol Oncol; 2021 Nov; 163(2):294-298. PubMed ID: 34518053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life after pelvic exenteration for gynecologic cancer: Findings from a qualitative study.
    Nelson AM; Albizu-Jacob A; Fenech AL; Chon HS; Wenham RM; Donovan KA
    Psychooncology; 2018 Oct; 27(10):2357-2362. PubMed ID: 29956389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival after pelvic exenteration for gynecologic malignancy.
    Westin SN; Rallapalli V; Fellman B; Urbauer DL; Pal N; Frumovitz MM; Ramondetta LM; Bodurka DC; Ramirez PT; Soliman PT
    Gynecol Oncol; 2014 Sep; 134(3):546-51. PubMed ID: 25014540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pelvic exenteration: long-term oncological results in a series of 106 patients.
    De Wever I
    Acta Chir Belg; 2011; 111(5):282-7. PubMed ID: 22191128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
    Wu MH; Shen WT; Gosnell J; Duh QY
    Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients.
    Chiantera V; Rossi M; De Iaco P; Koehler C; Marnitz S; Ferrandina G; Legge F; Parazzini F; Scambia G; Schneider A; Vercellino GF
    Int J Gynecol Cancer; 2014 Jun; 24(5):916-22. PubMed ID: 24442006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration.
    Donati OF; Lakhman Y; Sala E; Burger IA; Vargas HA; Goldman DA; Andikyan V; Park KJ; Chi DS; Hricak H
    Eur Radiol; 2013 Oct; 23(10):2906-15. PubMed ID: 23652852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration.
    Husain A; Akhurst T; Larson S; Alektiar K; Barakat RR; Chi DS
    Gynecol Oncol; 2007 Jul; 106(1):177-80. PubMed ID: 17477959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.